Table 5 The number of potential drugs filtered by meta-analysis for early- and late- stage NSCLC using the enrichment score (ES) and cMap p-value (less than 0.1) for meta-analysis

ES < 0 & cMap p-value <0.1

9

4

31

5

ES < 0 & cMap p-value <0.5

12

4

81

8

ES < 0 & p _MA -value <0.05

25

2

23

1

ES < 0 & p _MA -value <0.1

60

8

49

5